Press |

Lutetium-177 PSMA-617 resultaten eerste prospectieve studie

Over Lutetium-177 zijn veel vragen, het wachten is op studieresultaten. Op ASCO GU 2019 werden de resultaten gepresenteerd van de eerste prospectieve studie met Lutetium-177 PSMA-617 (LuPSMA). Deze kleinschalige single-centre studie met 50 patiënten die al docetaxel, cabazitaxel en abiraterone of enzalutamide hadden gehad, toonde een Overall Survival van 13,3 (9 mnd) maanden na behandeling.

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer

ALEXANDRIA, Va. – A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treatments for men with metastatic prostate cancer. According to the researchers, men receiving the medication lived a median of 13.3 months after treatment, longer than the average 9-month survival time for men with this stage of disease.

Abstract: Results of a 50 patient single-centre phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Pilot studie februari 2020

In februari 2020 werden de resultaten gepresenteerd van een pilot studie met een hyperfractionated (opgedeelde) dosering:

Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.

De conclusie luidt: ‘Hyperfractionation of 177 Lu-J591 is feasible but does not seem to have significant advantages over the two-dose fractionation regimen.’

Op ASCO GU 2020 (13-15 februari) worden meer resultaten verwacht van Lutetium-177 onderzoeken. Houdt hiervoor de site en de nieuwsbrief in de gaten.

Meer op DUOS

© 2020, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in